Copyright
©The Author(s) 2016.
World J Gastroenterol. Jul 7, 2016; 22(25): 5790-5799
Published online Jul 7, 2016. doi: 10.3748/wjg.v22.i25.5790
Published online Jul 7, 2016. doi: 10.3748/wjg.v22.i25.5790
Table 2 First treatment modalities for recurrent hepatocellular carcinoma after liver transplantation n (%)
| Treatments | Curative | Palliative |
| (n = 15, 27.8%) | (n = 39, 72.2%) | |
| Operation | 13 (86.7) | 1 (2.6) |
| Operation and radiation | 1 (6.7) | 4 (10.3) |
| Operation and TACE | 1 (2.6) | |
| TACE | 8 (20.5) | |
| TACE and RFA | 1 (6.7) | 1 (2.6) |
| Radiation | 7 (17.9) | |
| Intravenous chemotherapy | 5 (12.8) | |
| Sorafenib | 8 (20.5) | |
| Conservative treatment | 4 (10.3) |
- Citation: Na GH, Hong TH, You YK, Kim DG. Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation. World J Gastroenterol 2016; 22(25): 5790-5799
- URL: https://www.wjgnet.com/1007-9327/full/v22/i25/5790.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i25.5790